Biosimilar of Remicade Works in Ankylosing Spondylitis
CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis (AS), a multinational study found.
News
ANA Negative Lupus Nephritis - Does it Exist?
A recent report from the Mayo Clinic describes a 49 year-old patient with lupus nephritis who presented with new-onset hypertension, edema, arthritis, serositis and leukocytoclastic vasculitis, and who later developed glomerulonephritis and nephrotic syndrome.
Ultrasound Predicts Inflammatory Arthritis in CCP+ Persons Without Synovitis
A prospective study of 136 people who were CCP+, but who had no clinical evidence of synovitis, examined what factors may predict future development of inflammatory arthritis.
NIH-Funded Trials Down, While Industry Trials Increase
(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows.
Updated RA Treat-to-Target International Recommendations
In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).
Risk of Multiple Sclerosis with TNF Inhibitor Therapy
Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi).
Biosimilar Reports - January 2016
Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.
UK Audit Shows Early RA Referrals Still Too Slow
A national audit of rheumatoid arthritis (RA) and early inflammatory arthritis patients included 6,354 patients drawn from 143 trusts and health boards in England and Wales. Early arthritis clinics exist in 57% of trusts.
PML is Very Rare in Lupus
A systematic review of the literature was done to assess the relationship between immunosuppressive therapy, adult systemic lupus erythematosus (SLE) and the onset of progressive multifocal leukoencephalopathy.
TNF Inhibitors May Increase Cardiac Risks in Elderly
A retrospective study of elderly rheumatoid arthritis (RA) patients on Medicare was conducted by a group of researchers from the University of Alabama.
ASBMR Guidance on Bisphosphonate Use
The American Society of Bone and Mineral Research (ASBMR) Task Force has issued a guidance report on the use of bisphosphonates (BP) with a focus on the risk vs. benefits of such therapy. (Citation source http://buff.ly/1Nn0CVb)
PALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.
